Patients with cirrhosis can experience sudden and severe deterioration, progressing from acute decompensation to acute-on-chronic liver failure. However, the biological mechanisms underlying this transition are not fully understood.

In a new study from the DECISION project, we investigated whether epigenetic regulation, specifically DNA methylation, could help explain differences in disease progression.

Epigenetics refers to molecular mechanisms that regulate gene activity without altering the DNA sequence itself. One such mechanism, DNA methylation, involves the addition of small chemical tags that can activate or silence genes.

By analyzing DNA methylation patterns in patients with acute decompensation of cirrhosis, we observed that patients with worse outcomes exhibited higher global DNA methylation, suggesting a broad shift in gene regulation. In addition, specific epigenetic changes were identified near genes involved in key biological processes, including inflammation, immune response, metabolism, and liver function.

These findings highlight the role of epigenetic regulation in the progression of advanced liver disease and suggest that integrating molecular data may improve disease monitoring and risk stratification in the future.

🎥 Watch the video!
📖 We’ll link the paper once it’s published.

Metabolic dysfunction–associated steatohepatitis (MASH), part of the MASLD spectrum, is a rapidly growing cause of chronic liver disease worldwide. As fat accumulates in the liver and inflammation progresses, patients may develop cirrhosis and life-threatening complications.

Despite the increasing burden of disease, therapeutic options remain extremely limited, with weight reduction currently the only effective intervention for many patients. In this video, co-first author of the paper, Dr. med. Frank E. Uschner, presents a novel, standardized animal model for MASH-cirrhosis developed within the DECISION project.

Unlike traditional models, which often require long induction times and lack reproducibility, this model replicates key features of metabolic liver disease, including stearosis, inflammation, and liver damage, within approximately eight weeks.

By accelerating and standardizing disease development, this model provides a valuable platform to test new therapeutic strategies more efficiently and safely before translation into human clinical trials. Improving preclinical models is a crucial step toward better drug development, and ultimately toward improved patient care in MASH.

📖 Read our publication here:
https://www.mdpi.com/2073-4409/13/20/1707

🎥 Watch the video: